logo

Tag : industry data

The Growth Rate Disparity

Carlton Hoyt 11:11 am , May 29, 2015

Having compiled quite an extensive amount of published life science market size data, we’ve noticed a lot of very optimistic growth rates. That led me to wonder if that optimism is warranted, given overall growth in life science R&D, or if there’s something about published market reports that cause them to overstate growth rates.

As I’m sure many of us realize, life science R&D spending isn’t exactly skyrocketing. According to the Battelle and R&D Magazine “2014 Global R&D Funding Forecast” life science R&D spending has only rose from $184.2 billion in 2011 to $201.3 billion in 2014. This equates to a 3.00% compound annual growth rate. All else being equal, we should expect to see published life science market growth rates hovering around that, with the exceptional outlier for high-growth markets. It stands to reason that growth in the markets for life science tools and services should be in line with the growth in overall R&D spending.

To determine if the published studies hold to this, we took our list of published market size data and cleaned it using the following criteria:

  • Only global market size data were considered. All regional market size data were removed.
  • All studies not listing a growth rate were removed.
  • All studies publishing data from 2008 or earlier were removed. We only wanted to look at fairly recent data, roughly in line with the time frame of the R&D spending data from Battelle.
  • Only the newest study of a particular market from any given publisher was included. If XYZ Reports had a study of the cell culture market from both 2011 and 2013, only the 2013 report data was included.
  • If there was data for a directly related market and sub-markets from the same publisher, only the overarching market was taken. For instance, if data for the cell culture market and for the cell culture media market existed from XYZ reports, we would ignore the cell culture media market data in favor of the broader cell culture market data.


This data cleaning still left us with quite a large amount of data – 104 studies. These studies projected an average growth rate of 11.2%, far higher than the 3.00% increase in life science R&D spending. Weighted by the value of the market size estimate, the weighted average was still 10.4%, again far greater than life science R&D growth. In fact, the lowest growth rate from those 104 studies was 4.0% (a 2012 BCC Research study of the electrophoresis market and a 2013 Decibio study of the Life Science Research Tools Market). Even the lowest published growth rates are higher than the growth in life science R&D spending. This makes absolutely no sense.

There are a few potential ways in which our analysis may be flawed, either by bias or by failing to consider all realities. For instance:

  • The data we compile only includes studies that make public the market sizes and growth rates. This excludes a number of market research companies operating in the life sciences space. While our analysis included 104 studies, these studies all came from only 7 companies. Still, there is no evidence that these growth rate estimates are far higher than the estimates from any other companies.
  • Some of these market sizes may include growth from outside the life science R&D sector, such as diagnostics or life science (pharma / biotech) manufacturing. While this may be true in part, it does not explain the size of the disparity. With the exception of certain high-growth sub-markets, such as biosimilar manufacturing, IVD and manufacturing growth rates are both generally predicted to be in the mid single digits.
  • Companies which publish research may be focusing on “hot” markets and more likely to release studies on those high-growth markets. This is potentially a source of bias, however there are many very well-established markets included in this analysis (cell culture, research antibodies, chromatography, electrophoresis, microscopy, etc.) and even those markets have growth rates higher than the overall life science R&D market. The same can be said for market studies that analyze the life science tools and services markets at a very broad level, such as “Life Science Research Tools,” “Life Science & Chemical Instrumentation,” “Laboratory Equipment,” and “Preclinical Outsourcing.”
  • Decreases (or deceleration) in life science R&D funding may be disproportionately applied across R&D costs. It may be the case that spending on products and services tends to be more resistant to budgetary contractions than personnel, infrastructure, and other sources of cost. We do not believe this to be true, however, as much equipment and service spending is far easier to cut than staff or space.


In conclusion, we believe that it is very likely that life science growth rates are overstated in published reports, perhaps by as much as a factor of two. While we can’t be certain why such overestimates exist as we do not know how the studies were performed, we do know that they are not remotely in line with overall life science R&D growth rates and the discrepancy is very unlikely to be explained by other mitigating factors. The next time you use a commercially sold study to gauge growth rates, you may want to take them with a grain of salt and assume that they are an overestimate.

"The quality of your data will directly affect the quality of your decision-making. To obtain the best quality data, look to the people that have the most focused industry experience. BioBM conducts market research only within the life science tools and services sector. This exclusive focus means we know your market better than most (or all) other agencies, enabling us to provide superior data and analysis because we know what questions to ask. We better understand your needs, your markets and your customers, and better understanding is the whole point. Take the first step towards enlightenment."
Blog / Market Research 11:11 am , May 29, 2015

State of LS Tools Survey Results

Carlton Hoyt 11:33 pm , June 5, 2012

In mid-April, we discussed how despite the presence large amounts of negativity in the life science tools market, things actually appeared to be getting better. To follow that up, we conducted a brief 6-question survey last month to determine if people within the sector felt similarly and try to gauge if companies were preparing for better times or worse times ahead.

The survey was open from May 1st through May 31st. 22 respondents completed the survey. One respondent’s set of responses was removed from the survey due to not responding in the affirmative to the qualifying question which asked respondents if they worked within the life science tools and services market. Based on IP, 14 respondents were from North America, 6 were from Europe, and one was from Asia.

The questions (aside from the qualifying question) and responses are below:

1) Complete the following statement: “Thus far in 2012, my company’s sales have _____.”

2) Complete the following statement: “Compared to the last quarter of 2011, I feel _______ about the life science tools market”

3) Compared to the first half of 2012, how much does your company intend to spend on the following functions in the second half of 2012?

More Same Less
R&D 33.3% 57.1% 9.5%
Marketing 38.1% 47.6% 14.3%
Sales 57.1% 33.3% 9.5%

 

4) Which of the following is presently true about your company?

Additionally, two respondents left comments at the end of the survey. One noted “The market seems stable at the moment. We are mildly optimistic about the future.” The other stated “There are significant cuts in the research budgets.” The latter statement allows for some confusion as to whether “research budgets” referred to mean the academic research budgets or the budgets for internal R&D, although use of the plural leads us to believe the respondent most likely meant academic research budgets.

We find these results very interesting. While year-to-date performance in the respondents’ companies tends towards under-performance, perceptions compared to the previous year are roughly flat but companies are hiring and will be spending more. This could be due to any of multiple factors. For example, companies could be re-hiring and increasing budgets as a rebound from previous, overly conservative budget cuts. In other words, companies may have planned for a situation that was worse than the present, and therefore even though the present situation may not be good, hiring and increased spending have become necessary. Another common macroeconomic cause for increased hiring is decreasing workforce productivity. Additionally, some companies may increase spending in response to increases in spending at competitors in order to “keep up with the competition.” This discrepancy could also simply be a flaw in the survey, or perhaps a real difference in perception between the overall attitudes of life science tools companies and individual employees. There are many possible explanations, and we simply do not have enough data to evaluate all of the possible causes. All are free to draw their own conclusions.

Regardless, while the responses about company performance and the perception of the overall life science tools market are tepid, we are encouraged by the trend towards hiring and increased spending, and hope that companies rightfully see a reason to continue to invest in future growth.

Blog / Marketing Strategy 11:33 pm , June 5, 2012

Life Sci Tools Market Outlook

Carlton Hoyt 10:15 am , April 16, 2012

There’s been a lot of negativity in the life science tools market recently, at least with regards to the economic outlook. European government austerity, a possible US sequester, and cooling Asian economies have given a lot of people a sense of unease (or downright fear) about sector growth. Over the past two months, however, there’s a bunch of data that says things probably aren’t going to be so bad after all.

Back in late February, a MarketsandMarkets study projected the life science and chemical instrumentation market to grow at a compound annual growth rate (CAGR) of 8.4% from 2011 to 2016. Morgan Stanley analyst Daniel Brennan then noted in early March that commercial sales of publicly traded life science instrument companies had been stronger than expected and is less vulnerable to the economy than many had feared. A DeciBio study released last week projected that the life science tools market will grow by about 4% per year over the next 5 years. Sure, 4% isn’t a great growth rate, but it’s certainly enough to sustain the industry. Last Thursday, Goldman Sachs analyst Isaac Ro said that company performance in the life science tools industry for the first quarter of 2012 “appears to have trended better than initially expected” and noted that academic spending trends have improved.

While I wouldn’t go so far as to say that we’re in the clear, and there are certainly still hurdles the industry faces moving forward, we can all breathe a collective sigh of relief. The life science tools market isn’t in nearly as bad of shape as many had feared.

"Looking for growth in a challenging economy? Turn to BioBM Consulting. Our life science business and marketing experts can help your company develop and execute strategies that create demand and drive revenues regardless of external factors. Contact BioBM for more information."
Blog / Marketing Strategy 10:15 am , April 16, 2012